|
Male
|
91 (27%)
|
15 (24%)
|
76 (28%)
|
0.50
|
|
Age (years)
|
47.5 ± 17.6
|
41.4 ± 15.7
|
49.0 ± 17.8
|
0.0020
|
|
Basic EPS
|
|
Dual AV-nodal conduction
|
314 (94%)
|
57 (90%)
|
257 (95%)
|
0.19
|
|
At least 1 echo-beat
|
288 (86%)
|
43 (68%)
|
245 (90%)
|
< 0.0001
|
|
2 or more echo-beats
|
191 (57%)
|
0 (0%)
|
191 (70%)
|
< 0.0001
|
|
AVNRT induction
|
146 (44%)
|
0 (0%)
|
146 (54%)
|
< 0.0001
|
|
Cycle length of AVNRT (ms)
|
386 ± 63
|
n.a.
|
386 ± 63
|
n.a.
|
|
Metaproterenol administration
|
145 (43%)
|
58 (92%)
|
87 (32%)
|
< 0.0001
|
|
Dual AV-nodal conduction
|
144/145 (99%)
|
57/58 (98%)
|
87/87 (100%)
|
0.40
|
|
Only after metaproterenol adm.
|
18/145 (12%)
|
5/58 (9%)
|
13/87 (15%)
|
0.26
|
|
At least 1 echo-beat
|
135/145 (93%)
|
50/58 (86%)
|
85/87 (98%)
|
0.015
|
|
Only after metaproterenol adm.
|
36/145 (25%)
|
12/58 (21%)
|
24/87 (28%)
|
0.35
|
|
2 or more echo-beats
|
44/145 (30%)
|
0/58 (0%)
|
44/87 (51%)
|
< 0.0001
|
|
Only after metaproterenol adm.
|
33/145 (23%)
|
0/58 (0%)
|
33/87 (38%)
|
< 0.0001
|
|
AVNRT induction
|
18/145 (12%)
|
0/58 (0%)
|
18/87 (21%)
|
0.0002
|
|
Cycle length of AVNRT (ms)
|
379 ± 74
|
n.a.
|
379 ± 74
|
n.a.
|
